How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/elvitegravir-cobicistat-emtricitabine-tenofovir-disoproxil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil (elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (integrase inhibitor + pharmacokinetic booster + nucleoside/nucleotid

marketed Antiretroviral combination (integrase inhibitor + pharmacokinetic booster + nucleoside/nucleotide reverse transcriptase inhibitors) HIV integrase, CYP3A4, HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil (elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil) — Fundacion Clinic per a la Recerca Biomédica. This fixed-dose combination inhibits HIV integrase, protease, and reverse transcriptase while blocking viral entry, suppressing HIV replication through multiple mechanisms.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil TARGET	elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil	Fundacion Clinic per a la Recerca Biomédica	marketed	Antiretroviral combination (integrase inhibitor + pharmacokinetic booster + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, CYP3A4, HIV reverse transcriptase
elvitegravir/cobicistat/emtricitabine/tenofovir	elvitegravir/cobicistat/emtricitabine/tenofovir	Juan A. Arnaiz	marketed	Antiretroviral combination (INSTI + pharmacokinetic booster + NRTIs)	HIV integrase, CYP3A4, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (integrase inhibitor + pharmacokinetic booster + nucleoside/nucleotide reverse transcriptase inhibitors) class)

Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil — Competitive Intelligence Brief. https://druglandscape.com/ci/elvitegravir-cobicistat-emtricitabine-tenofovir-disoproxil. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab